Randomised controlled trial of Compensatory Cognitive Training and a Computerised Cognitive Remediation programme

Trials

Veronica De Monte¹  Frances Dark¹  Victoria Gore-Jones¹  Marta I. Garrido²  Ilvana Dzafic²  Ellie Newman³ 

[1] Metro South Addiction and Mental Health Services, 228 Logan Road, Woolloongabba, Queensland, Australia;Queensland Brain Institute, Centre for Advanced Imaging, Centre of Excellence for Integrative Brain Function, The University of Queensland, Brisbane, Queensland, Australia;Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia;St Kilda Road Clinic, Community Adult Mental Health, Alfred Psychiatry, Melbourne, Australia;

关键词: Cognitive remediation;    Schizophrenia;    Cognitive functioning;    Neurocognition;   

DOI  :  10.1186/s13063-020-04743-y

来源: Springer

【 摘 要 】

BackgroundCompensation and adaptation therapies have been developed to improve community functioning via improving neurocognitive abilities in people with schizophrenia. Various modes of delivering compensation and adaptation therapies have been found to be effective. The aim of this trial is to compare two different cognitive interventions, Compensatory Cognitive Training (CCT) and Computerised Interactive Remediation of Cognition–Training for Schizophrenia (CIRCuiTS). The trial also aims to identify if mismatch negativity (MMN) can predict an individual’s response to the compensation and adaptation programmes.MethodsThis study will use a randomised, controlled trial of two cognitive interventions to compare the impact of these programmes on measures of neurocognition and function. One hundred clinically stable patients aged between 18 and 65 years with a diagnosis of a schizophrenia spectrum disorder will be recruited. Participants will be randomised to either the CCT or the CIRCuiTS therapy groups. The outcome measures are neurocognition (BACS), subjective sense of cognitive impairment (SSTICS), social functioning (SFS), and MMN (measured by EEG) in people with schizophrenia spectrum disorders.DiscussionThis trial will determine whether different approaches to addressing the cognitive deficits found in schizophrenia spectrum disorders are of comparable benefit using the outcome measures chosen. This has implications for services where cost and lack of computer technology limit the implementation and dissemination of interventions to address cognitive impairment in routine practice. The trial will contribute to the emerging evidence of MMN as a predictor of response to cognitive interventions.Trial registrationAustralian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12618000161224. Registered on 2 February 2018. Protocol version: 4.0, 18 June 2018.

【 授权许可】

CC BY